

Annual report
30/12/2025

ANNUAL REPORT 2024

DETAILS

Antivenom Foundation	Reg: 1204543
Period start	24/12/2024
Period end	30/12/2025

INTRODUCTION

Snakebite envenoming alone kills an estimated 81,000–138,000 people every year and leaves over 400,000 survivors with permanent disabilities, according to the World Health Organization. Other venomous animals—such as scorpions, spiders, and marine species— can also cause significant harm, particularly in rural and resource-limited settings. The only effective treatment for envenoming is antivenom, but it is difficult to produce, expensive, and often unavailable in regions that need it most. Many areas suffer chronic shortages or have no coverage at all, leaving vulnerable communities without life-saving antidotes.

This year marked another step forward as we continued laying the foundations for our long-term mission to improve access to effective antivenoms in regions where envenomation remains a critical public health challenge. While we are still in the early stages, our efforts have focused on supporting research, regulatory submissions, and building partnerships that will lay the ground for the future.

OBJECTIVES AND ACTIVITIES

Summary of charity purpose

The primary aim of the Antivenom Foundation is to establish the world’s first international antivenom stockpile mechanism, ensuring timely access to effective treatments that prevent death and disability caused by bites and stings from venomous animals. In pursuit of this goal, the foundation also works to support patients, physicians, and local organizations, while advancing research, education, and awareness on the issue of animal envenomation.

Summary of main activities

Our goal is ambitious, and we are only at the beginning of what will be a long and challenging journey. In this second year of activity, the foundation has built on last year’s progress by supporting initial safety studies in Lebanon, preparing submissions for antivenom approval in sub-Saharan Africa, expanding our network of international experts, and contributing to education and knowledge-sharing initiatives.

Statement on Charity commission guidance on public benefit

The Trustees confirm that, in exercising their powers and duties, they have had due regard to the guidance on public benefit issued by the Charity Commission for England and Wales. The Trustees



Annual report
30/12/2025

are satisfied that the charity's activities have been carried out in a manner that aligns with the public benefit requirement set out in the Charity Commission's guidelines.

In making decisions, the Trustees have considered both the aims and the activities of the charity, ensuring that they are for the public benefit and that the charity's resources are used effectively to further its charitable purposes.

ACHIEVEMENTS AND PERFORMANCE

Summary of main achievements

As with the previous year our main achievements in this period have come from the ability of the foundation to draw on a network of international expert volunteers providing small but meaningful contributions that have made a significant difference on the ground.

Sub-Saharan Africa: Our experts continued to assist the University of Costa Rica with regulatory submissions for antivenom in sub-Saharan Africa—a major focus that required significant time and expertise. As part of this effort, we collaborated with local partners in Eswatini to collect and analyse data from their successful implementation of a new antivenom. Regulatory documents are now ready for submission to the local authorities, pending completion of refurbishments at the production plant to allow inspection.

Regional networks: We strengthened engagement with medical toxicology networks across sub-Saharan Africa, and the MENA region with our volunteers invited to join key expert groups. This is an important step toward understanding challenges on the ground. Additionally, we provided speakers for educational seminars organized by local partners in Eswatini and South Africa, helping to raise awareness and share knowledge.

Levant: We provided administrative support to the American University of Beirut (AUB) for safety testing of a new antivenom formulation. This initial study was very small-scale but successful, identifying important issues related to packaging, logistics, handling, and study design that need resolution before larger trials can proceed. With limited effective antivenoms available for the region, we understand that larger humanitarian organizations are now exploring ways to advance this work as they are desperately in need of an effective antivenom for this region.

FINANCIAL REVIEW

Review of financial position

The Antivenom Foundation is still a start-up charity in the process of setting up, it therefore has not undertaken any substantial fundraising or activities that incurred any expense. Thanks to donation platforms we raised more funds than last year—though still very modest, these resources are being held in reserve until we have sufficient capital to undertake more substantial projects.



Annual report
30/12/2025

Reserves policy

Currently the foundation has no formal reserves policy as we have been focused on supporting activities and have not raised significant funds or incurred any overheads. Should this position change in the future then the trustees will develop a reserves policy as appropriate.

Going concerns

The economic environment continues to present challenges for the charity sector, particularly for start-up organisations like ours. Opportunities for grant funding remain limited, and our international focus on neglected diseases further narrows the pool of potential donors. Antivenom is inherently expensive, meaning substantial funds will need to be raised before we can begin fulfilling our primary objective of providing antivenom to those in need.

Despite these challenges, the foundation operates with minimal overheads and currently incurs no significant expenses. We continue to provide a valuable nucleus that connects local organizations with global experts, enabling progress in research, regulatory processes, and knowledge sharing. While fundraising remains difficult and current reserves are modest, the foundation benefits from a committed team of volunteers who are prepared for the long journey ahead.

For these reasons, the trustees remain confident in the charity’s ability to continue operating and advancing its mission over the coming year.

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Antivenom Foundation is a Charitable Incorporated Organisation (CIO) governed by constitution. Trustees are appointed for a term of 3 years by majority resolution passed at a properly convened meeting of the charity trustees. In selecting individuals for appointment as charity trustees, the charity trustees must have regard to the skills, knowledge and experience needed for the effective administration of the CIO.

REFERENCE AND ADMINISTRATIVE DETAILS

Antivenom Foundation (AVF)

Reg: 1204543

Address

11 Spring Grove
Godalming
GU7 3SS

Trustees	Active from	Term
Faisa Price	31/8/2023	4 years
Steven Swallow	31/8/2023	3 Years
Alessia Cacioni	7/01/2024	3 years



Annual report
30/12/2025

FUNDS HELD AS CUSTODIAN TRUSTEES ON BEHALF OF
OTHERS

Not applicable

DECLARATIONS

The trustees declare that they have approved the trustees’ report above.

Trustee: Faisa Price

Trustee: Steven Swallow

Signed:

DocuSigned by:

Faisa Price

7E5E26216188439...

Signed:

DocuSigned by:

Steve Swallow

11DECDD7036844D...





CHARITY COMMISSION
FOR ENGLAND AND WALES

Antivenom Foundation

1204543

Receipts and payments accounts

CC16a

For the period
from

12/24/24


To

12/30/25

Section A Receipts and payments

	Unrestricted funds	Restricted funds	Endowment funds	Total funds	Last year
	to the nearest £	to the nearest £	to the nearest £	to the nearest £	to the nearest £
A1 Receipts					
Donations	3,617	-	-	3,617	157
Cash reserve from previous year	157	-	-	157	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
Sub total (Gross income for AR)	3,774	-	-	3,774	157
A2 Asset and investment sales, (see table).					
	-	-	-	-	-
	-	-	-	-	-
Sub total	-	-	-	-	-
Total receipts	3,774	-	-	3,774	157
A3 Payments					
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
Sub total	-	-	-	-	-
A4 Asset and investment purchases, (see table)					
	-	-	-	-	-
	-	-	-	-	-
Sub total	-	-	-	-	-
Total payments	-	-	-	-	-
Net of receipts/(payments)	3,774	-	-	3,774	157
A5 Transfers between funds	-	-	-	-	-
A6 Cash funds last year end	-	-	-	-	-
Cash funds this year end	3,774	-	-	3,774	157

Section B Statement of assets and liabilities at the end of the period

Categories	Details	Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
B1 Cash funds	Donations	3,617	-	-
	Cash reserve from previous year	157	-	-
		-	-	-
	Total cash funds	3,774	-	-
	(agree balances with receipts and payments account(s))	OK	OK	OK
		Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
B2 Other monetary assets	Details	-	-	-
		-	-	-
		-	-	-
		-	-	-
		-	-	-
		-	-	-
B3 Investment assets	Details	Fund to which asset belongs	Cost (optional)	Current value (optional)
			-	-
			-	-
			-	-
			-	-
B4 Assets retained for the charity's own use	Details	Fund to which asset belongs	Cost (optional)	Current value (optional)
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
B5 Liabilities	Details	Fund to which liability relates	Amount due (optional)	When due (optional)
			-	
			-	
			-	
			-	
Signed by one or two trustees on behalf of all the trustees		Signature	Print Name	Date of approval
		DocuSigned by:  7E5E26216188439...	Faiza Price	30/12/2025